Compare Moderna, Inc. (MRNA) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs PepsiCo, Inc. — how do they compare? Moderna, Inc. trades at $225.25 (market cap $78.65B), while PepsiCo, Inc. trades at $126.06 (market cap $174.89B). The key difference: PepsiCo, Inc. is far larger — about 2.2× Moderna, Inc.'s market cap, and PepsiCo, Inc. pays a 4.61% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and PepsiCo, Inc. for 107 Days on average.
| MRNA | PEP | |
|---|---|---|
Market Cap | $78.65B | $174.89B |
Volume | 37,373,437 | 23,968,864 |
Sector | Health | Consumer Staples |
52-Week High | $203.46 | $170.44 |
52-Week Low | $22.36 | $123.64 |
Typical Hold Time | 59 Days | 107 Days |
Enterprise Value | $74.80B | $215.61B |
Dividend Yield | — | 4.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
PepsiCo (PEP) trades at $125.97, up 1.88% today, with a bearish technical signal but strong fundamentals. The stock shows consistent earnings beats, with Q3 2026 EPS of $2.34 exceeding the $2.29 estimate. Revenue grew to $93.93B in 2025, though net income margin dipped to 8.77%. Analysts maintain a consensus price target of $146.77, implying significant upside. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while institutional holdings saw mixed adjustments.
The outlook for PEP is cautiously optimistic, driven by earnings momentum and a reasonable P/E of 16.14. Risks include competitive pressures and sensitivity to consumer spending. The stock offers a dividend yield near 4%, supporting income-focused investors. Upside potential exists if North American performance improves, but volatility may persist amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
